Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Salvador J, et al. Among authors: bayo j. Clin Transl Oncol. 2015 Feb;17(2):160-6. doi: 10.1007/s12094-014-1210-x. Epub 2014 Aug 14. Clin Transl Oncol. 2015. PMID: 25119930 Clinical Trial.
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Blancas I, et al. Among authors: bayo jl. Clin Transl Oncol. 2018 Jul;20(7):862-869. doi: 10.1007/s12094-017-1797-9. Epub 2017 Nov 24. Clin Transl Oncol. 2018. PMID: 29178019
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM. Ruíz-Borrego M, et al. Breast Cancer Res Treat. 2019 Aug;177(1):115-125. doi: 10.1007/s10549-019-05296-8. Epub 2019 May 31. Breast Cancer Res Treat. 2019. PMID: 31152327 Clinical Trial.
Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaen A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M. Blancas I, et al. Among authors: bayo jl. Clin Transl Oncol. 2018 Dec;20(12):1631-1632. doi: 10.1007/s12094-018-1956-7. Clin Transl Oncol. 2018. PMID: 30284231 Free article.
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabé R, Vicente D, Jiménez J, Lopez-Ladrón A. Ruiz M, et al. Among authors: bayo j. Cancer Chemother Pharmacol. 2008 Nov;62(6):1085-90. doi: 10.1007/s00280-008-0709-7. Epub 2008 Mar 26. Cancer Chemother Pharmacol. 2008. PMID: 18365200 Clinical Trial.
SEOM clinical guidelines to primary prevention of cancer (2018).
Bayo J, Molina R, Pérez J, Pérez-Ruíz E, Aparicio J, Beato C, Berros JP, Bolaños M, Graña B, Santaballa A. Bayo J, et al. Clin Transl Oncol. 2019 Jan;21(1):106-113. doi: 10.1007/s12094-018-02016-4. Epub 2019 Jan 3. Clin Transl Oncol. 2019. PMID: 30607789 Free PMC article.
SEOM clinical guideline for secondary prevention (2019).
Santaballa A, Pinto Á, Balanyà RP, Ramírez Merino N, Martín IR, Grau SS, Fombella JPB, Cano JM, González CH, Bayo J. Santaballa A, et al. Among authors: bayo j. Clin Transl Oncol. 2020 Feb;22(2):187-192. doi: 10.1007/s12094-020-02302-0. Epub 2020 Jan 31. Clin Transl Oncol. 2020. PMID: 32006339 Free article.
136 results